The global viral inactivation market was valued at USD 320.5 Million in 2016 and poised to grow at a CAGR of 12.3% between 2016 and 2021, to reach USD 573.0 Million in 2021. Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics. Еще
